Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 6 Results

Title
Intervention Indication Therapeutic Area Year Actions
Dupilumab for Children Aged 12 Years to 17 Years with Moderate to Severe Atopic Dermatitis Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893) Atopic dermatitis Dermatology 2018 View  |  Download
Dupilumab for children aged 6 to less than 12 years with severe atopic dermatitis Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893) Atopic dermatitis Dermatology 2019 View  |  Download
Dupilumab for treating Chronic Spontaneous Urticaria in people aged 12 years and older after 1 previous treatment Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893) Chronic spontaneous urticaria (CSU) Dermatology 2021 View  |  Download
Dupilumab for treating eosinophilic oesophagitis in people aged 12 years and older Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893) Eosinophilic oesophagitis Gastroenterology , Immunology 2022 View  |  Download
Dupilumab for treating Prurigo Nodularis Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893) Prurigo nodularis (PN) Dermatology 2021 View  |  Download
Dupilumab in addition to controller medications for children aged 6 to 11 years with asthma controller medications , Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893) Asthma Respiratory System 2021 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications